You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物拉漲近8%創新高,或將與禮來製藥共同宣佈六項達伯舒最新臨牀研究成果
uSMART友信智投 09-16 10:45

uSMART友信智投9月16日消息,週三港股,信達生物繼續延續強勁走勢,截至10:42分,信達生物盤中拉漲近8%,最高觸及67.2港元,股價再創新高。

值得注意的是,昨日信達生物在尾盤一度漲近9%。

消息面,信達生物(01801)和禮來製藥(LLY.US)將於9月19日至21日的2020年歐洲腫瘤內科學會(ESMO)年會上,共同宣佈六項關於達伯舒(信迪利單抗注射液)的最新臨牀研究成果。

據悉,ESMO大會是歐洲最負盛名和最具影響力的腫瘤學會議之一,屆時衆多來自全球各地的臨牀醫生、研究人員等腫瘤學專家將對腫瘤治療領域最新研究進展進行分享與交流。

此外,在已獲悉的2020 ESMO會議安排中,達伯舒®(信迪利單抗注射液)共有6項研究入選,包括2項最新突破性摘要(LBA,mini oral)以及4項電子壁報(e-poster),其中包括2項正在進行中的III期研究。研究覆蓋的腫瘤領域包括:肺癌、肝細胞癌、胃癌、婦科腫瘤、其他實體瘤等等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account